Just Do It Already, Pfizer | GenomeWeb

Derek Lowe, like many, is waiting to see how the Pfizer layoffs will pan out. Planning for months now to cut research staff, Pfizer still hasn't lowered the ax, but Lowe predicts that the changes will be "quite profound in chemistry. Pfizer seems to be dividing its chemists up into people who think up molecules, and people who make them, with no real overlap," he writes at In the Pipeline. He also predicts that outsourcing will be taken to a whole new level.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.